Paper Details

  1. Home
  2. Paper Details

Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy.

Author: BurgessLesley J, CeskaRichard, Chasan-TaberScott, Gouni-BertholdIoanna, McGowanMary P, SoranHandrean, TardifJean-Claude, WagenerGilbert

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Mipomersen is an antisense oligonucleotide that targets apolipoprotein B synthesis. This drug significantly reduces LDL-C and other atherogenic lipoproteins in patients with familial hypercholesterolemia when added to ongoing lipid-lowering therapy. This study evaluated the safety and efficacy of mipomersen in patients with severe hypercholesterolemia.
Paper Details　
Original Abstract of the Article :
Mipomersen, an antisense oligonucleotide targeting apolipoprotein B synthesis, significantly reduces LDL-C and other atherogenic lipoproteins in familial hypercholesterolemia when added to ongoing maximally tolerated lipid-lowering therapy. Safety and efficacy of mipomersen in patients with severe h...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3496741/

データ提供：米国国立医学図書館（NLM）

Mipomersen: A New Weapon in the Fight Against High Cholesterol

This research focuses on mipomersen, a novel drug that targets the production of apolipoprotein B (apoB), a key protein involved in the formation of harmful cholesterol (LDL-C). It's like a tiny missile that zeroes in on the source of the problem, reducing LDL-C levels in people with severe hypercholesterolemia, even those already on other cholesterol-lowering medications.

Mipomersen: Showing Promise in the Battle Against Cholesterol

The study demonstrates that mipomersen is effective in reducing LDL-C levels in patients with severe hypercholesterolemia, even when other therapies have reached their limit. This is a significant advancement in the fight against heart disease, as it offers a new treatment option for those who need it most.

Heart Health: A Crucial Aspect of Well-being

High cholesterol can lead to serious health issues, including heart disease. Mipomersen's ability to effectively reduce LDL-C levels provides a valuable tool for healthcare professionals to manage this condition and protect patients' heart health. It's like a shield protecting the heart from the dangers of high cholesterol.

Dr.Camel's Conclusion

Mipomersen is a promising addition to the arsenal of tools available to combat high cholesterol. It offers a new line of defense for individuals with severe hypercholesterolemia, helping to reduce their risk of heart disease and improving their overall cardiovascular health.
Date :
  1. Date Completed 2013-05-01
  2. Date Revised 2023-11-06
Further Info :

Pubmed ID

23152839

DOI: Digital Object Identifier

PMC3496741

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.